Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Werewolf Therapeutics, Inc. Market Cap
The Werewolf Therapeutics, Inc. (HOWL) share price is expected to increase by 435.71% over the next year. This is based on calculating the average 12-month share price estimate provided by 0 stock analysts who have covered HOWL. Price targets range from $8 at the low end to $15 at the high end. The current analyst consensus for HOWL is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
Werewolf Therapeutics, Inc. has a total of 0 Wall St Analyst ratings. There are 0 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a sell consensus rating, the expectation is that Werewolf Therapeutics, Inc. will perform worse than the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of HOWL.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Andres Maldonado HC Wainwright & Co. | Buy | $15 | Reiterates | Jul 2, 2024 |
| Reni Benjamin JMP Securities | Market Outperform | $12 | Reiterates | Jun 26, 2024 |
| Andres Maldonado HC Wainwright & Co. | Buy | $15 | Reiterates | Jun 26, 2024 |
| Reni Benjamin JMP Securities | Market Outperform | $12 | Reiterates | Jun 4, 2024 |
| Andres Maldonado HC Wainwright & Co. | Buy | $15 | Reiterates | Jun 3, 2024 |
| Andres Maldonado HC Wainwright & Co. | Buy | $15 | Reiterates | May 24, 2024 |
| Andres Maldonado HC Wainwright & Co. | Buy | $15 | Reiterates | May 6, 2024 |
| Reni Benjamin JMP Securities | Market Outperform | $12 | Reiterates | May 6, 2024 |
| Reni Benjamin JMP Securities | Market Outperform | $12 | Initiates | Apr 3, 2024 |
| Andres Maldonado HC Wainwright & Co. | Buy | $15 | Maintains | Mar 7, 2024 |
| Andres Maldonado HC Wainwright & Co. | Buy | $15 | Reiterates | Nov 15, 2023 |
| Andres Maldonado HC Wainwright & Co. | Buy | $15 | Reiterates | Oct 31, 2023 |
| Andres Maldonado HC Wainwright & Co. | Buy | $15 | Reiterates | Sep 19, 2023 |
| Andres Maldonado HC Wainwright & Co. | Buy | $15 | Reiterates | Sep 15, 2023 |
Wedbush | Outperform | Initiates | Aug 24, 2023 | |
HC Wainwright & Co. | Buy | Reiterates | Aug 10, 2023 | |
| Michael King EF Hutton | Buy | $8.3 | Assumes | May 25, 2023 |
B of A Securities | Buy | Reiterates | May 15, 2023 | |
| Jason Zemansky B of A Securities | Buy | $10 | Maintains | May 12, 2023 |
| Andres Maldonado HC Wainwright & Co. | Buy | $15 | Reiterates | May 11, 2023 |
When did it IPO
2021
Staff Count
45
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Daniel J. Hicklin Ph.D.
Market Cap
$97.5M
In 2023, HOWL generated $19.9M in revenue, which was a increase of 21.60% from the previous year. This can be seen as a signal that HOWL's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
No news data available.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
